Anecortave

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Anecortave
Accession Number
DB12081
Type
Small Molecule
Groups
Investigational
Description

Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).

Structure
Thumb
Synonyms
Not Available
External IDs
AL 4940 / AL-4940
Categories
UNII
R5Y8O51589
CAS number
10184-70-0
Weight
Average: 344.451
Monoisotopic: 344.198759382
Chemical Formula
C21H28O4
InChI Key
BCFCRXOJOFDUMZ-ONKRVSLGSA-N
InChI
InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1
IUPAC Name
(2S,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1(17),6-dien-5-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Anecortave is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Anecortave.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Anecortave.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Anecortave.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Anecortave.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Anecortave.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Anecortave.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Anecortave.Approved, Withdrawn
AldesleukinAnecortave may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Anecortave can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Anecortave can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Anecortave can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Anecortave.Experimental
AloglutamolThe bioavailability of Anecortave can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Anecortave.Experimental
AluminiumThe bioavailability of Anecortave can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Anecortave can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Anecortave can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Anecortave can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Anecortave is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Anecortave.Approved
AmiodaroneThe serum concentration of Anecortave can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BAnecortave may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Anecortave.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Anecortave.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Anecortave.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Anecortave.Approved, Investigational
AprepitantThe serum concentration of Anecortave can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Anecortave can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Anecortave.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Anecortave.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Anecortave.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Anecortave.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Anecortave is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Anecortave.Experimental
BendroflumethiazideAnecortave may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Anecortave.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Anecortave.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Anecortave.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Anecortave.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Anecortave.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Anecortave.Experimental
Bismuth SubcitrateThe bioavailability of Anecortave can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Anecortave can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Anecortave can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Anecortave.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Anecortave.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Anecortave.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Anecortave.Experimental
BumetanideAnecortave may increase the hypokalemic activities of Bumetanide.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anecortave.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Anecortave.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Anecortave can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Anecortave can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideAnecortave may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Anecortave can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Anecortave.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Anecortave.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anecortave.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Anecortave.Approved, Investigational
CeritinibAnecortave may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Anecortave.Approved, Vet Approved
ChlorothiazideAnecortave may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Anecortave can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneAnecortave may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Anecortave.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Anecortave can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Anecortave.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Anecortave is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Anecortave can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Anecortave can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Anecortave.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Anecortave is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Anecortave is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Anecortave.Investigational
CyclopenthiazideAnecortave may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Anecortave.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Anecortave.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Anecortave.Investigational
DaidzeinThe serum concentration of Anecortave can be increased when it is combined with Daidzein.Experimental
DanazolAnecortave may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Anecortave can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Anecortave is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Anecortave is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Anecortave is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Anecortave.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Anecortave.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Anecortave is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Anecortave.Approved, Vet Approved
DienestrolThe serum concentration of Anecortave can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Anecortave can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Anecortave.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anecortave.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Anecortave.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Anecortave.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Anecortave.Approved
DihydrotestosteroneAnecortave may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Anecortave is combined with Distigmine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anecortave.Approved, Investigational
DonepezilThe risk or severity of adverse effects can be increased when Anecortave is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Anecortave.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Anecortave.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Anecortave.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Anecortave is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Anecortave is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Anecortave can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Anecortave can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Anecortave.Approved
EquolThe serum concentration of Anecortave can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Anecortave can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Anecortave can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Anecortave can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Anecortave can be increased when it is combined with Estrone.Approved
Etacrynic acidAnecortave may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Anecortave.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Anecortave.Experimental
Ethinyl EstradiolThe serum concentration of Anecortave can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Anecortave.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Anecortave.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Anecortave.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Anecortave.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Anecortave.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Anecortave.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Anecortave.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Anecortave.Approved
FenthionThe risk or severity of adverse effects can be increased when Anecortave is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Anecortave.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Anecortave.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Anecortave.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Anecortave.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Anecortave is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Anecortave.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Anecortave.Experimental
FluoxymesteroneAnecortave may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Anecortave.Approved, Investigational
FosaprepitantThe serum concentration of Anecortave can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Anecortave can be decreased when it is combined with Fosphenytoin.Approved
FurosemideAnecortave may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Anecortave is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Anecortave is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Anecortave is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Anecortave can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Anecortave is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Anecortave.Experimental
GLPG-0492Anecortave may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Anecortave.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Anecortave.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Anecortave.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Anecortave is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Anecortave is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Anecortave can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Anecortave.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Anecortave is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Anecortave.Approved, Investigational
HydrochlorothiazideAnecortave may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAnecortave may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Anecortave can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Anecortave.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Anecortave.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Anecortave.Approved
IdelalisibThe serum concentration of Anecortave can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Anecortave.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Anecortave.Approved
IndapamideAnecortave may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Anecortave can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Anecortave.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Anecortave.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Anecortave.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Anecortave is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Anecortave is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Anecortave is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Anecortave is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Anecortave.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Anecortave.Withdrawn
ItraconazoleThe serum concentration of Anecortave can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Anecortave.Experimental
KetoconazoleThe serum concentration of Anecortave can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Anecortave.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Anecortave.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Anecortave.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Anecortave.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Anecortave.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Anecortave.Experimental
LopinavirThe serum concentration of Anecortave can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Anecortave.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Anecortave.Approved, Investigational
LumacaftorThe serum concentration of Anecortave can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Anecortave.Approved, Investigational
MagaldrateThe bioavailability of Anecortave can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Anecortave can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Anecortave can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Anecortave can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anecortave.Approved
Magnesium silicateThe bioavailability of Anecortave can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Anecortave can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Anecortave is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Anecortave.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anecortave.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Anecortave.Approved
MefloquineThe risk or severity of adverse effects can be increased when Anecortave is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Anecortave.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Anecortave is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Anecortave.Approved
MesteroloneAnecortave may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Anecortave can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Anecortave.Investigational, Withdrawn
MethallenestrilThe serum concentration of Anecortave can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Anecortave is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideAnecortave may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Anecortave.Approved, Vet Approved
MethyltestosteroneAnecortave may increase the fluid retaining activities of Methyltestosterone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Anecortave.Experimental
MetoclopramideThe risk or severity of adverse effects can be increased when Anecortave is combined with Metoclopramide.Approved, Investigational
MetolazoneAnecortave may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Anecortave can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Anecortave is combined with Minaprine.Approved
MitotaneThe serum concentration of Anecortave can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Anecortave.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Anecortave.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Anecortave.Experimental
MoxestrolThe serum concentration of Anecortave can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anecortave.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anecortave.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Anecortave.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Anecortave.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Anecortave.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Anecortave is combined with Nalidixic Acid.Approved, Investigational
NandroloneAnecortave may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateAnecortave may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Anecortave.Approved, Vet Approved
NefazodoneThe serum concentration of Anecortave can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Anecortave can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Anecortave is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Anecortave.Approved
NevirapineThe serum concentration of Anecortave can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Anecortave is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Anecortave.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Anecortave.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Anecortave.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Anecortave.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Norfloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Anecortave.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anecortave.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Anecortave.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Anecortave.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Anecortave.Approved
OxandroloneAnecortave may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Anecortave.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Anecortave is combined with Oxolinic acid.Experimental
OxymetholoneAnecortave may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anecortave.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anecortave.Approved, Vet Approved
ParaoxonThe risk or severity of adverse effects can be increased when Anecortave is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Anecortave.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Anecortave.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Anecortave can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Anecortave.Experimental
PhenobarbitalThe serum concentration of Anecortave can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Anecortave.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Anecortave.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Anecortave.Approved, Investigational
PhenytoinThe serum concentration of Anecortave can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Anecortave is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anecortave.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Anecortave is combined with Pipemidic acid.Experimental
PiretanideAnecortave may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anecortave.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Anecortave is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Anecortave.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Anecortave.Experimental
Polyestradiol phosphateThe serum concentration of Anecortave can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAnecortave may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Anecortave can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Anecortave.Experimental, Investigational
PrimidoneThe serum concentration of Anecortave can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Anecortave.Experimental
PromestrieneThe serum concentration of Anecortave can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Anecortave.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Anecortave.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Anecortave.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Anecortave.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Anecortave.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Anecortave is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Anecortave can be increased when it is combined with Quinestrol.Approved
QuinethazoneAnecortave may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Anecortave is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Anecortave.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Anecortave.Approved, Experimental, Investigational
RifabutinThe serum concentration of Anecortave can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Anecortave can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Anecortave can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Anecortave is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Anecortave is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Anecortave.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Anecortave is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Anecortave is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Anecortave.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Anecortave.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Anecortave is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Anecortave.Approved
SaquinavirThe serum concentration of Anecortave can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Anecortave can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Anecortave.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Anecortave.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Anecortave.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Anecortave can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Anecortave is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Anecortave.Investigational
St. John's WortThe serum concentration of Anecortave can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololAnecortave may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Anecortave can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Anecortave.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Anecortave.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Anecortave.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Anecortave.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Anecortave can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Anecortave can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Anecortave is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Anecortave.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Anecortave is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Anecortave.Approved, Withdrawn
TelithromycinThe serum concentration of Anecortave can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Anecortave.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Anecortave.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Anecortave.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Anecortave.Approved
TestosteroneAnecortave may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateAnecortave may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Anecortave is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Anecortave.Approved
TiboloneThe serum concentration of Anecortave can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Anecortave.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Anecortave.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Anecortave.Approved
TorasemideAnecortave may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Anecortave.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Anecortave.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Anecortave.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Anecortave is combined with Trichlorfon.Vet Approved
TrichlormethiazideAnecortave may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Anecortave.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Anecortave.Approved
TromethamineThe bioavailability of Anecortave can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Anecortave is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Anecortave is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Anecortave.Investigational, Withdrawn
VoriconazoleThe serum concentration of Anecortave can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAnecortave may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Anecortave is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anecortave.Approved, Investigational
ZeranolThe serum concentration of Anecortave can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Anecortave.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Anecortave.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Anecortave is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
7074810
PubChem Substance
347828387
ChemSpider
5428328
ChEMBL
CHEMBL2348782
ATC Codes
S01LA02 — Anecortave

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0334 mg/mLALOGPS
logP2.98ALOGPS
logP2.18ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.66 m3·mol-1ChemAxon
Polarizability38.24 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones / Cyclic alcohols and derivatives / Primary alcohols / Organic oxides
show 1 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / Cyclohexenone / Alpha-hydroxy ketone / Cyclic alcohol
show 11 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:19 / Updated on November 09, 2017 05:01